

10/53844

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 May 2004 (21.05.2004)

PCT

(10) International Publication Number
WO 2004/041213 A3

(51) International Patent Classification⁷: C12N 15/00,
G01N 33/53, 33/567, A61K 49/00

(21) International Application Number:
PCT/US2003/035294

(22) International Filing Date:
4 November 2003 (04.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/424,031 4 November 2002 (04.11.2002) US

(71) Applicants (for all designated States except US):
BIOARCTIC NEUROSCIENCE AB [SE/SE]; Lag-
mansvagen 13, S-18163 Lidingo (SE). **ICOGENEX**
CORPORATION [US/US]; 454 North 34th Street, Seat-
tle, WA 98103 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HAGEN**, Freder-
ick, S. [US/US]; 1315 Lexington Way East, Seattle, WA
98112 (US). **LANNFELT**, Lars [SE/SE]; Vintertullstor-
get 28, S-11643 Stockholm (SE). **GELLERFORS**, Par
[SE/SE]; Lagmansvagen 13, S-18163 Lidingo (SE).

(74) Agents: **POOR**, Brian, W. et al.; **TOWNSEND** and
TOWNSEND and **CREW**, LLP, Two Embarcadero Center,
8th Floor, San Francisco, CA 94111 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (BW, GH,
GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,
SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

— with international search report
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(88) Date of publication of the international search report:
23 December 2004

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: METHODS FOR THE IDENTIFICATION OF AGENTS THAT MODULATE THE STRUCTURE AND PROCESSING
OF BETA-AMYLOID PRECURSOR PROTEIN

(57) Abstract: The present invention provides methods for the screening and identification of agents from a large library of molecu-
lar structures that can alter the cleavage of amyloid precursor protein (AP). Agents identified by the methods of the present invention
that modify the cleavage of APP can be used in the treatment and prevention of Alzheimer's disease. The methods select for and
identify effector agents that bind to APP causing a structural change in the structure of APP in such a way that the efficiency of the
cleavage of a secretase is modulated. Further, the methods are carried out in an in vivo system that provides for physiological condi-
tions similar or identical to conditions for APP processing. Agents can be selected for their ability to cause a decrease in the amount
of B-secretase or γ -secretase cleavage of APP, or for an increase in a-secretase cleavage of APP. The agents can be, particularly
peptide agents, can be converted into a peptidomimetic, an isosteric replacement compound, a D-amino acid analog, or non-peptidyl
compound for treating Alzheimer's disease or any other amyloid related or prion related disease. The agents or derivatives thereof
can be formulated for intravenous, parenteral, topical, sustained release, intranasal, or inhalation use.

WO 2004/041213 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/35294

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : C12N 15/00; G01N 33/53, 33/567; A61K 49/00 US CL : 435/7.1, 7.21, 172.3; 530/350; 800/3 According to International Patent Classification (IPC) or to both national classification and IPC																	
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 435/7.1, 7.21, 172.3; 530/350; 800/3 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EAST, MEDLINE																	
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1"> <thead> <tr> <th>Category *</th> <th>Citation of document, with indication, where appropriate, of the relevant passages</th> <th>Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td>X — Y</td> <td>US 6,440,698 B1 (GURNEY et al) 27 August 2002 (27.08.2002), column 10, lines 30-59; column 7, lines 34-46; column 35, line 7 to column 36, line 21.</td> <td>1-7, 36-38, 46 ----- 15-35, 39-45, 53-61</td> </tr> <tr> <td>X — Y</td> <td>US 6,175,057 B1 (MUCKE et al) 16 January 2001 (16.01.2001), column 16, lines 1-58; column 19, lines 35-39; column 16, lines 31-33; column 12, line 6 to column 13, line 61; column 17, lines 1-16.</td> <td>1, 8-14, 63 ----- 42-45, 49-50, 59-60</td> </tr> <tr> <td>X — Y</td> <td>US 5,604,102 A (MCCONLOGUE et al) 18 February 1997 (18.02.1997), column 9, line 16 to column 11, line 14; column 11, lines 28-42.</td> <td>1, 47-48, 51-52, 62 ----- 49-50</td> </tr> <tr> <td>Y</td> <td>US 2002/0127564 A1 (NOLAN) 12 September 2002 (12.09.2002), entire document, especially page 2, paragraph 25 and 27; page 3, paragraphs 37-38; page 4, paragraphs 41-45; page 5, paragraphs 51-53; page 11, paragraphs 105-107.</td> <td>15-20, 22-35, 50, 53-56, 58</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X — Y	US 6,440,698 B1 (GURNEY et al) 27 August 2002 (27.08.2002), column 10, lines 30-59; column 7, lines 34-46; column 35, line 7 to column 36, line 21.	1-7, 36-38, 46 ----- 15-35, 39-45, 53-61	X — Y	US 6,175,057 B1 (MUCKE et al) 16 January 2001 (16.01.2001), column 16, lines 1-58; column 19, lines 35-39; column 16, lines 31-33; column 12, line 6 to column 13, line 61; column 17, lines 1-16.	1, 8-14, 63 ----- 42-45, 49-50, 59-60	X — Y	US 5,604,102 A (MCCONLOGUE et al) 18 February 1997 (18.02.1997), column 9, line 16 to column 11, line 14; column 11, lines 28-42.	1, 47-48, 51-52, 62 ----- 49-50	Y	US 2002/0127564 A1 (NOLAN) 12 September 2002 (12.09.2002), entire document, especially page 2, paragraph 25 and 27; page 3, paragraphs 37-38; page 4, paragraphs 41-45; page 5, paragraphs 51-53; page 11, paragraphs 105-107.	15-20, 22-35, 50, 53-56, 58
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.															
X — Y	US 6,440,698 B1 (GURNEY et al) 27 August 2002 (27.08.2002), column 10, lines 30-59; column 7, lines 34-46; column 35, line 7 to column 36, line 21.	1-7, 36-38, 46 ----- 15-35, 39-45, 53-61															
X — Y	US 6,175,057 B1 (MUCKE et al) 16 January 2001 (16.01.2001), column 16, lines 1-58; column 19, lines 35-39; column 16, lines 31-33; column 12, line 6 to column 13, line 61; column 17, lines 1-16.	1, 8-14, 63 ----- 42-45, 49-50, 59-60															
X — Y	US 5,604,102 A (MCCONLOGUE et al) 18 February 1997 (18.02.1997), column 9, line 16 to column 11, line 14; column 11, lines 28-42.	1, 47-48, 51-52, 62 ----- 49-50															
Y	US 2002/0127564 A1 (NOLAN) 12 September 2002 (12.09.2002), entire document, especially page 2, paragraph 25 and 27; page 3, paragraphs 37-38; page 4, paragraphs 41-45; page 5, paragraphs 51-53; page 11, paragraphs 105-107.	15-20, 22-35, 50, 53-56, 58															
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																	
* Special categories of cited documents: <table border="0"> <tr> <td> "A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			"A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family													
"A" document defining the general state of the art which is not considered to be of particular relevance "B" earlier application or patent published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family																
Date of the actual completion of the international search 26 September 2004 (26.09.2004)		Date of mailing of the international search report 19 OCT 2004															
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer Zachary D Howard Telephone No. 571-272-2877															

INTERNATIONAL SEARCH REPORT

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6,420,110 B1 (GYURIS et al) 16 July 2002 (16.07.02) entire document, especially column 2, lines 31-33; column 19, lines 22-29; column 43, lines 22-24; column 18, lines 11-29; column 9, lines 36-37; column 3, lines 35-37.	21, 24, 28, 32, 45, 58, 61
Y	RIAN, E et al. A Signal Sequence Trap Based on Cell Enrichment Using Anti-CD19 Antibody Coated Magnetic Beads. Scand. J. Immunol. September 2001, Vol. 54, pages 280-284, entire document.	26
Y	PONCET, C. CD24, a glycosphosphatidylinositol-anchored molecule is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors. Acta Neuropathol. 1996, Vol. 91, No. 4, Abstract only.	30
Y	MURTHY, S.C. Characterization of the interleukin 3 receptor. Exp. Hematol. January 1990, Vol. 18, No. 1, Abstract only.	31
Y	MAZUR-KOLECKA, B. et al. Accumulation of Alzheimer amyloid-peptide in cultured myocytes is enhanced by serum and reduced by cerebrospinal fluid. J Neuropathol Exp Neurol. March 1997, Vol. 56, No. 3, Abstract only.	39-41, 57, 60